Stem Cell Therapeutics Initiates Enrollment in Phase IIb Stroke Trial
Posted on: Thursday, 29 May 2008, 09:01 CDT
Canada-based Stem Cell Therapeutics has enrolled the first patient in its Regenesis Phase IIb stroke trial.
The Regenesis trial is a double-blind, randomized, placebo-controlled Phase IIb clinical trial for Stem Cell Therapeutics's (SCT) lead program, NTx-265, for the treatment of acute ischemic stroke.
The Regenesis Phase IIb stoke trial will be a multi-site trial projected to enroll 134 patients at approximately 18 Canadian sites. A similar US Phase IIb acute ischemic stroke trial was recently approved by the FDA and is projected to enroll 20-30 patients at three-four enrolling US sites. The Canadian and US Phase IIb clinical stroke studies share similar protocols, safety and efficacy endpoints.
SCT is recruiting patients for the multi-centre, double-blind, placebo-controlled Regenesis Phase IIb stroke study for NTx-265 with primary endpoints of efficacy. Patient enrollment is expected to be complete by the end of 2008 with top-line efficacy data expected to be released before the end of the first quarter of 2009.
Allen Davidoff, vice president of product development at SCT, said: "We hope the Regenesis Phase IIb trial will build upon the promising results from the Betas Phase IIa trial by demonstrating the positive effect that NTx-265 exerts on recovery of visual, motor and cognitive recovery in patients who have suffered moderate to severe acute ischemic stroke."
Source: Datamonitor
Related Articles
- Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
- Genta Updates Progress of Its Phase 3 Trial of Genasense(R) in Patients With Advanced Melanoma
- Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
- Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
- Genta Announces New Phase 3 Trial of Genasense(R) in Patients With Advanced Melanoma
- Exelixis Reports Additional Data From a Phase I Trial of XL647 in Patients With Advanced Solid Tumors
- Patient Accrual Completed into Phase 3 Trial of Genasense(R) in Patients With Acute Myeloid Leukemia
- Metabolex Initiates Phase 2/3 Trial of Metaglidasen in Patients With Type 2 Diabetes
- Nuvelo and Bayer HealthCare Begin SONOMA-3, Second Phase 3 Trial of Alfimeprase in Patients With Central Venous Catheter Occlusion
 |
 |
User Comments (0)
RSS Feeds